Fig. 2From: Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancerProgression-free survival from initiation of 2 L treatment. a PFS with monotherapy, doublet therapy, triplet therapy, and overall; b PFS with taxane monotherapy, irinotecan monotherapy, fluoropyrimidine + irinotecan, and fluoropyrimidine + platinumBack to article page